Humana Inc. (NYSE:HUM) to Issue Quarterly Dividend of $0.89

Humana Inc. (NYSE:HUM) announced a quarterly dividend on Thursday, February 20th,RTT News reports. Stockholders of record on Friday, March 28th will be given a dividend of 0.885 per share by the insurance provider on Friday, April 25th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.33%.

Humana has raised its dividend by an average of 8.1% per year over the last three years. Humana has a payout ratio of 24.8% indicating that its dividend is sufficiently covered by earnings. Analysts expect Humana to earn $13.16 per share next year, which means the company should continue to be able to cover its $3.54 annual dividend with an expected future payout ratio of 26.9%.

Humana Stock Performance

Shares of HUM stock opened at $265.54 on Thursday. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana has a 12-month low of $213.31 and a 12-month high of $406.46. The business’s 50 day moving average is $269.80 and its two-hundred day moving average is $291.28. The company has a market capitalization of $31.97 billion, a P/E ratio of 26.69, a P/E/G ratio of 1.94 and a beta of 0.56.

Humana (NYSE:HUM) last announced its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Analysts expect that Humana will post 16.49 EPS for the current fiscal year.

Analyst Ratings Changes

HUM has been the topic of several research reports. Piper Sandler raised their target price on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research report on Wednesday, January 15th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $283.00 target price on shares of Humana in a research note on Wednesday, February 12th. Wells Fargo & Company reduced their target price on shares of Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Barclays raised their price target on shares of Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 13th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research note on Tuesday. Nineteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Humana presently has an average rating of “Hold” and a consensus target price of $285.68.

Insider Buying and Selling at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. This represents a 31.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.32% of the stock is currently owned by corporate insiders.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.